Palatin Technologies

$0.454
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0274 (+6.60%) Today
+$0.0116 (+2.62%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell PTN and other stocks, options, and ETFs commission-free!

About PTN

Palatin Technologies, Inc., also called Palatin Technologies, is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ. The listed name for PTN is Palatin Technologies, Inc.

CEO
Carl Spana
Employees
20
Headquarters
Cranbury, New Jersey
Founded
1986
Market Cap
101.71M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.87M
High Today
$0.4539
Low Today
$0.413
Open Price
$0.413
Volume
2.97M
52 Week High
$0.83
52 Week Low
$0.355

Collections

PTN Earnings

-$0.03
$0.06
$0.14
$0.23
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
-$0.03 per share
Actual
-$0.02 per share

You May Also Like